Cellectis to present clinical data on lasme-cel, eti-cel at EHA Congress

Cellectis (CLLS) announced upcoming presentations on the BALLI-01 and NATHALI-01 clinical trials, at the European Hematology Association annual congress, on June 11-14, 2026, in Stockholm, Sweden. The abstract reporting the full Phase 1 dataset from the BALLI-01 clinical trial evaluating lasme-cel, a CD22 directed allogeneic CAR-T, in heavily pretreated patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia, has been selected for oral presentation. These data, which will be presented by Nitin Jain, M.D., Professor of Medicine, Department of Leukemia at MD Anderson Cancer Center in Houston, highlight the promising safety profile and response rates in patients who have relapsed following multiple prior targeted therapies including autologous CD19 CAR-T. They form the basis for the pivotal Phase 2 program which is currently recruiting in Europe and North America. The BALLI-01 trial is currently recruiting in Pivotal Phase 2 with interim data expected to be disclosed in Q4 2026.The abstract from the Phase 1 NATHALI-01 study evaluating eti-cel in patients with relapsed or refractory B-cell non-Hodgkin lymphoma has been accepted for poster presentation. This preliminary analysis explores the relationship between alemtuzumab exposure, eti-cel cellular expansion, cytokine dynamics, and clinical outcomes, providing early mechanistic insights into the optimization of the lymphodepletion regimen for this best-in-class dual-targeting CD20/CD22 allogeneic CAR T-cell product. The Phase 1 clinical data of the NATHALI-01 clinical trial are planned to be disclosed in Q4 2026.